This blog is part of our Month of CIRM series, which features our Agency’s progress towards achieving our mission to accelerate stem cell treatments to patients with unmet medical needs. This week, we’re highlighting CIRM-funded clinical trials to address the growing interest in our rapidly expanding clinical portfolio. Our Agency has funded a total of … Continue reading CIRM-Funded Clinical Trials Targeting Brain and Eye Disorders
jCyte
CIRM-funded life-saving stem cell therapy gets nod of approval from FDA
If you have read our 2016 Annual Report (and if you haven’t you should, it’s brilliant) or just seen the cover you’ll know that it features very prominently a young girl named Evie Padilla Vaccaro. Evie was born with Severe Combined Immunodeficiency or SCID – also known as “bubble baby disease”; we’ve written about it … Continue reading CIRM-funded life-saving stem cell therapy gets nod of approval from FDA
Throwback Thursday: Progress to a Cure for Diseases of Blindness
Welcome back to our “Throwback Thursday” series on the Stem Cellar. Over the years, we’ve accumulated an arsenal of exciting stem cell stories about advances towards stem cell-based cures for serious diseases. This month we’re featuring stories about CIRM-funded clinical trials for blindness. 2017 has been an exciting year for two CIRM-funded clinical trials that … Continue reading Throwback Thursday: Progress to a Cure for Diseases of Blindness
jCyte gets FDA go-ahead for Fast Track review process of Retinitis Pigmentosa stem cell therapy
When the US Congress approved, and President Obama signed into law, the 21st Century Cures Act last year there was guarded optimism that this would help create a more efficient and streamlined, but no less safe, approval process for the most promising stem cell therapies. Even so many people took a wait and see approach, … Continue reading jCyte gets FDA go-ahead for Fast Track review process of Retinitis Pigmentosa stem cell therapy
jCyte starts second phase of stem cell clinical trial targeting vision loss
Studies show that Americans fear losing their vision more than any other sense, such as hearing or speech, and almost as much as they fear cancer, Alzheimer’s and HIV/AIDS. That’s not too surprising. Our eyes are our connection to the world around us. Sever that connection, and the world is a very different place. For … Continue reading jCyte starts second phase of stem cell clinical trial targeting vision loss
California’s stem cell agency rounds up the year with two more big hits
It’s traditional to end the year with a look back at what you hoped to accomplish and an assessment of what you did. By that standard 2016 has been a pretty good year for us at CIRM. Yesterday our governing Board approved funding for two new clinical trials, one to help kidney transplant patients, the … Continue reading California’s stem cell agency rounds up the year with two more big hits
How stem cells are helping change the face of medicine, one pioneering patient at a time
One of the many great pleasures of my job is that I get to meet so many amazing people. I get to know the researchers who are changing the face of medicine, but even more extraordinary are the people who are helping them do it, the patients. Attacking Cancer It’s humbling to meet people like … Continue reading How stem cells are helping change the face of medicine, one pioneering patient at a time
CIRM-funded stem cell trial for retinitis pigmentosa makes progress
A CIRM-funded clinical trial for retinitis pigmentosa (RP), a degenerative eye disease that causes blindness, recently reached its next milestone and announced the completion of its patient enrollment for a phase I/IIa study testing a stem cell derived therapy. This is a major step forward in determining whether this approach is both safe and effective … Continue reading CIRM-funded stem cell trial for retinitis pigmentosa makes progress
CIRM-funded stem cell clinical trial for retinitis pigmentosa focuses on next stage
How retinitis pigmentosa erodes normal vision The failure rate for clinical trials is depressingly high. A study from Tufts University in 2010 found that for small molecules – the substances that make up more than 90 percent of the drugs on the market today – the odds of getting from a Phase 1 trial to … Continue reading CIRM-funded stem cell clinical trial for retinitis pigmentosa focuses on next stage
The Stem Cellar 